Breast Implants Safety Concerns – the Importance of Post-Marketing Surveillance
4th April 2019
Pharmacovigilance (QPPV) provision post-Brexit
7th February 2020
Yellow fever vaccine – following two fatalities – the vaccine must not be given to patients that present with a history of thymus dysfunction, or is immunosuppressed. The MHRA advise clinicians use extreme caution in administering the vaccine in people over 60 due to an increased risk of an Adverse Reaction – ADR
The use of Valoprate medicines pre and during pregnancy. Valoprate is a medicine used in the treatment of epilepsy and bipolar condition. It has been known that this drug causes significant birth defects in children born to patients using valproate. The MHRA has provided a revised Annual Risk Acknowledgement for clinicians to use on all females of childbearing age. They issued a reminder that there is no safe dose of valproate that can be used in pregnancy.
